Use of teprotumumab in thyroid eye disease
- PMID: 33953374
- DOI: 10.1038/s41574-021-00505-1
Use of teprotumumab in thyroid eye disease
Comment on
-
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.Lancet Diabetes Endocrinol. 2021 Jun;9(6):360-372. doi: 10.1016/S2213-8587(21)00056-5. Epub 2021 Apr 15. Lancet Diabetes Endocrinol. 2021. PMID: 33865501 Clinical Trial.
References
Original article
-
- Kahaly, G. et al. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(21)00056-5 (2021) - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
